RXO shareholders will receive just $17.25 per share in cash and 0.0856 shares of C.H. Robinson Worldwide common stock for each RXO share, representing an implied total consideration of $30.25 per share in a transaction valued at approximately $5.8 billion; Ademi LLP is investigating the deal price, benefits to company insiders, and restrictions on competing offers
CLICK HERE TO JOIN
MILWAUKEE, Oct. 5, 2026 /PRNewswire/ — Ademi LLP is investigating whether the proposed acquisition of RXO (NYSE: RXO) by C.H. Robinson, provides fair value to RXO’s public shareholders and whether RXO’s Board adequately protected shareholder interests in negotiating and approving the transaction.
Are You a RXO Shareholder?
If you own RXO shares, Ademi LLP would like to hear from you about the proposed acquisition and your rights as a shareholder.
You may also contact Guri Ademi at gademi@ademilaw.com or toll-free at 866-264-3995.
There is no cost or obligation to you.
What Is Ademi LLP Investigating?
The exchange ratio and whether it adequately reflects RXO’s value and future prospects;
Substantial change-of-control benefits available to RXO insiders in connection with the transaction;
Restrictions on competing transactions, including a significant termination penalty that may discourage another potential buyer from making a superior proposal; and
The conduct of RXO’s Board of Directors in negotiating and approving the transaction and whether the Board fulfilled its duties to public shareholders.
What Should RXO Shareholders Do?
Contact Ademi LLP to discuss your rights and our investigation. There is no cost or obligation to you.
Guri AdemiAdemi LLP
Toll Free: (866) 264-3995
Email: gademi@ademilaw.com
About Ademi LLP
Ademi LLP represents investors in shareholder litigation involving mergers, acquisitions, buyouts, and individual shareholder rights.
Attorney advertising. Prior results do not guarantee similar outcomes.
View original content to download multimedia:https://www.prnewswire.com/news-releases/rxo-shareholder-alert-ademi-llp-investigates-whether-buyout-fairly-values-rxo-inc-302898460.html
SOURCE Ademi LLP
